Robert Lavender Institution-verified

Grants & Funding

• A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin gargine/lixisenatide fixed rat Sanofi Pasteur, Inc. Principal Investigator
• A Phase III Randomized, double blind, parallel-group stuyd of the efficacy and safety of oral dabigatran etexilate (150 mg bid)compared to warffarin ( Boehringer Ingleheim Pharmaceuticals, Inc. Principal Investigator
• Protocol #11702 entitled: “Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis and/or pulmonary emboli Bayer Corporation (Bayer USA) Principal Investigator
• A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenati Sanofi-Aventis Principal Investigator
• A Phase III Randomized, double blind, parallel-group stuyd of the efficacy and safety of oral dabigatran etexilate (150 mg bid)compared to warffarin ( Boehringer Ingleheim Pharmaceuticals, Inc. Principal Investigator
• A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LM Daiichi Pharmaceutical Corporation Principal Investigator
• A double-blind, placebo-controlled, parallel, multicenter study on extended VTE prophylaxix in acutely ill medical patients with prolonged immobilizat Aventis Pharmaceuticals, Inc. Principal Investigator
• A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin gargine/lixisenatide fixed rat Sanofi Pasteur, Inc. Principal Investigator

Frequent Collaborators

Similar Researchers

Based on overlapping research topics